POLY(ACRYLAMIDE-CO-BUTADIENE-CO-ITACONIC ACID-CO-STYRENE)
General Information
| Mainterm | POLY(ACRYLAMIDE-CO-BUTADIENE-CO-ITACONIC ACID-CO-STYRENE) |
| CAS Reg.No.(or other ID) | 26713-54-2 |
| Regnum |
175.105 176.170 176.180 |
From www.fda.gov
Computed Descriptors
Download SDF| 2D Structure | |
| CID | 168593 |
| IUPAC Name | buta-1,3-diene;2-methylidenebutanedioic acid;prop-2-enamide;styrene |
| InChI | InChI=1S/C8H8.C5H6O4.C4H6.C3H5NO/c1-2-8-6-4-3-5-7-8;1-3(5(8)9)2-4(6)7;1-3-4-2;1-2-3(4)5/h2-7H,1H2;1-2H2,(H,6,7)(H,8,9);3-4H,1-2H2;2H,1H2,(H2,4,5) |
| InChI Key | LOWROEASPMAYAF-UHFFFAOYSA-N |
| Canonical SMILES | C=CC=C.C=CC1=CC=CC=C1.C=CC(=O)N.C=C(CC(=O)O)C(=O)O |
| Molecular Formula | C20H25NO5 |
From Pubchem
Computed Properties
| Property Name | Property Value |
|---|---|
| Molecular Weight | 359.422 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Complexity | 305.0 |
| CACTVS Substructure Key Fingerprint | A A A D c e B 6 O A A A A A A A A A A A A A A A A A A A A A A A A A A w A A A A A A A A A A A B A A A A H g A Q C A A A D A C B m A A w C I B A A g C I A i H S G A C C A A A g A A A I i A E A A M g I J D K A E R C A Y A A k 0 A A I m I d D g A A O A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = = |
| Topological Polar Surface Area | 118.0 |
| Monoisotopic Mass | 359.173 |
| Exact Mass | 359.173 |
| Compound Is Canonicalized | True |
| Formal Charge | 0 |
| Heavy Atom Count | 26 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Isotope Atom Count | 0 |
| Covalently-Bonded Unit Count | 4 |
From Pubchem
ADMET Predicted Profile --- Classification
| Model | Result | Probability |
|---|---|---|
| Absorption | ||
| Blood-Brain Barrier | BBB+ | 0.9042 |
| Human Intestinal Absorption | HIA+ | 0.7868 |
| Caco-2 Permeability | Caco2- | 0.5651 |
| P-glycoprotein Substrate | Non-substrate | 0.7197 |
| P-glycoprotein Inhibitor | Non-inhibitor | 0.9459 |
| Non-inhibitor | 0.9918 | |
| Renal Organic Cation Transporter | Non-inhibitor | 0.9470 |
| Distribution | ||
| Subcellular localization | Mitochondria | 0.6275 |
| Metabolism | ||
| CYP450 2C9 Substrate | Non-substrate | 0.9104 |
| CYP450 2D6 Substrate | Non-substrate | 0.8675 |
| CYP450 3A4 Substrate | Non-substrate | 0.6873 |
| CYP450 1A2 Inhibitor | Non-inhibitor | 0.9463 |
| CYP450 2C9 Inhibitor | Non-inhibitor | 0.8911 |
| CYP450 2D6 Inhibitor | Non-inhibitor | 0.8663 |
| CYP450 2C19 Inhibitor | Non-inhibitor | 0.9156 |
| CYP450 3A4 Inhibitor | Non-inhibitor | 0.8199 |
| CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.9806 |
| Excretion | ||
| Toxicity | ||
| Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9930 |
| Non-inhibitor | 0.9766 | |
| AMES Toxicity | Non AMES toxic | 0.9035 |
| Carcinogens | Non-carcinogens | 0.8686 |
| Fish Toxicity | High FHMT | 0.8076 |
| Tetrahymena Pyriformis Toxicity | Low TPT | 0.8601 |
| Honey Bee Toxicity | Low HBT | 0.6393 |
| Biodegradation | Ready biodegradable | 0.8082 |
| Acute Oral Toxicity | III | 0.6901 |
| Carcinogenicity (Three-class) | Non-required | 0.6134 |
From admetSAR
ADMET Predicted Profile --- Regression
| Model | Value | Unit |
|---|---|---|
| Absorption | ||
| Aqueous solubility | -1.9209 | LogS |
| Caco-2 Permeability | 0.5407 | LogPapp, cm/s |
| Distribution | ||
| Metabolism | ||
| Excretion | ||
| Toxicity | ||
| Rat Acute Toxicity | 1.9893 | LD50, mol/kg |
| Fish Toxicity | 1.8327 | pLC50, mg/L |
| Tetrahymena Pyriformis Toxicity | -0.7621 | pIGC50, ug/L |
From admetSAR